TLX Stock Forecast & Price Target

Telix Pharmaceuticals is supported by a strong core franchise in Illuccix and Gozellix, with 3Q26 revenue of $245MM, Precision Medicine revenue of $201MM, and management still guiding FY26 revenue and other income above $1B while expecting Precision Medicine growth of more than 25%. The company’s outlook is further strengthened by multiple catalysts, including Pixclara’s first U.S. commercial presence in neuro-oncology, BiPASS enrollment completion and FDA support for an NDA pathway, and near-term Zircaix resubmission alongside advancing programs in TLX591-Tx, TLX597-Tx, and TLX250-Tx. Strategically, the proposed $1.65B ITM acquisition should deepen vertical integration, improve isotope supply control, add a $273MM 2025 revenue business with >40% manufacturing gross margins, and broaden the pipeline with ITM-11.

Telix Pharmaceuticals is exposed to meaningful downside because its valuation depends heavily on a small number of clinical-stage programs and the continued success of its radiopharmaceutical pipeline in urologic oncology, neuro-oncology, musculoskeletal oncology and hematology. Clinical or regulatory setbacks in these programs could stall development, while failure to meet sales estimates would directly weaken the company’s revenue trajectory, especially given that most current revenue comes from Illuccix. This concentration in one commercial product, combined with execution risk across diagnostics and therapeutics, makes the outlook cautious and leaves the company vulnerable to both pipeline disappointments and underwhelming sales.